The effect of glucagon on the exocrine pancreas. A review.
Glucagon can depress normal animal and human pancreatic exocrine secretions and modify experimentally-induced pancreatitis in animals. It has yet to be demonstrated that glucagon has any efficacy in the treatment of the diseased pancreas in man. Glucagon might act on the exocrine pancreas by 1. reducing pancreatic blood flow, 2. decreasing gastric secretion, 3. lowering serum calcium levels by the release of calcitonin, 4. acting to inhibit the secretin mechanism, 5. causing a hyperglycemia and 6. degranulating pancreatic acinar cells. While a reduction in pancreatic blood flow, an inhibition of the secretin mechanism and a hyperglycemia seemed to have been ruled out as possible mechanisms of action, there is too little available data to effectively speculate on the mechanism(s) of action of glucagon on the exocrine pancreas.
D000208:Acute Disease; D000818:Animals; D002116:Calcitonin / Q000378:metabolism; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D005750:Gastric Juice / Q000378:metabolism; D005934:Glucagon / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D010182:Pancreatic Diseases / Q000188:drug therapy* / Q000503:physiopathology; D010189:Pancreatic Juice / Q000378:metabolism*; D010195:Pancreatitis / Q000188:drug therapy / Q000503:physiopathology; D012633:Secretin / Q000502:physiology; D012636:Secretory Rate / Q000187:drug effects
D012633:Secretin; D002116:Calcitonin; D005934:Glucagon; D002118:Calcium